Methods:
We examined prospective data from a cohort of 3,750 individuals with bipolar I or II disorder participating in the Systematic Treatment Enhancement Program for Bipolar Disorder study, selecting a subset of individuals who experienced two depressive episodes during up to two years of follow-up. Across-episode association of individual depressive or hypomanic ⁄ mixed symptoms was examined using the weighted kappa measure of agreement as well as logistic regression.
Results: A total of 583 subjects experienced two prospectively observed depressive episodes, with 149 of those subjects experiencing a third. Greatest evidence of stability was observed for neurovegetative features, suicidality, and guilt ⁄ rumination. Loss of interest and fatigue were not consistent across episodes. Structural equation modeling suggested that the dimensional structure of symptoms was not invariant across episodes.
Conclusion: While the overall dimensional structure of depressive symptoms lacks temporal stability, individual symptoms including suicidality, mood, psychomotor, and neurovegetative symptoms are stable across major depressive episodes in bipolar disorder and should be considered in future investigations of course and pathophysiology in bipolar disorder. (9, 10) , melancholia (11) , and suicidality (10) . To our knowledge, no study has specifically examined stability of these symptoms in bipolar depression, and only one study considered more than one depressive episode. Beyond refining psychiatric nosology, understanding temporal stability may facilitate biological studies by clarifying ÔcoreÕ symptoms of depression in mood disorders. It may also guide clinical practice if certain symptoms such as suicidality demonstrate stability from episode to episode. We therefore examined data from the multicenter Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) cohort study of bipolar disorder, utilizing the subset of individuals with up to three prospectively observed depressive episodes. We attempted to confirm the stability of neurovegetative symptoms and suicidality between episodes and explore the broader stability of mood symptoms.
Roy

Methods
Study overview
STEP-BD was a multicenter ÔeffectivenessÕ study conducted in the U.S. between 1999 and 2005 which evaluated prospective outcomes among individuals with bipolar disorder. Methods for the STEP-BD study as a whole are detailed elsewhere (12, 13) .
Participants
Study participation was offered to all bipolar patients seeking outpatient treatment at one of the participating study sites. Entry criteria included meeting DSM-IV criteria for bipolar disorder I, II, or not otherwise specified; cyclothymia; or schizoaffective disorder, bipolar type; and ability to provide informed consent. For individuals age 15-17, written assent was also required from parent or guardian. Hospitalized individuals were eligible to enter following discharge.
Assessments
Bipolar diagnosis was determined using mood and psychosis modules from the Structured Clinical Interview for DSM-IV (SCID) as incorporated into the Affective Disorders Evaluation (ADE) and confirmed by a second clinical rater using the Mini International Neuropsychiatric Interview (MINI) (12) . Comorbid Axis I diagnoses were also determined using the MINI. At each subsequent visit, clinicians assigned current mood status based upon the Clinical Monitoring Form (CMF) (14) , which assesses DSM-IV criteria for depressive, manic, hypomanic, or mixed states in the prior 14 days. Each criterion is scored on a 0-2 scale, where 1 represents threshold or syndromal by DSM-IV mood episode criteria; fractional scores are used to indicate subthreshold symptoms. Greatest reliability has been observed for three anchor points: 0 (symptoms absent), 0.5 (symptoms present but below DSM-IV threshold because of severity or frequency), and 1 (symptoms present at threshold or syndromal levels). For this reason, and to maximize interpretability and consistency with DSM-IV, the present analysis focused on scores quantized to one of these three levels. The CMF also examines proportion of time with clinically significant anxiety and irritability in the prior 10 days; these were also examined as continuous measures. Finally, the CMF also includes the Clinical Global Impression scale for Current Severity (CGI-S).
Intervention
Study clinicians in STEP-BD were trained to use model practice procedures, which included published pharmacotherapy guidelines (15), but they could prescribe any treatment which they felt to be indicated. Elsewhere, we have reported high concordance between treatment selection and guideline recommendations, indicating that patients received standard-of-care treatment when entering STEP-BD (16).
Outcomes
Because STEP-BD was intended to mimic clinical practice, participants were seen as frequently as clinically indicated. Clinical status was assessed at each follow-up visit with the CMF and was used to define the mood states which represent the primary outcome measure. Remission (defined in other STEP-BD reports as recovery, or durable recovery) was defined as two or fewer syndromal features of mania, hypomania, or depression for at least eight weeks, consistent with standard DSM-IV criteria for partial or full remission and with criteria used in the prior NIMH Collaborative Study of Depression (17) . Recurrence was defined as meeting full DSM-IV criteria for a manic, hypomanic, mixed, or depressive episode on any one follow-up visit.
Statistical analysis
In total, 4,107 subjects entered STEP-BD, including 3,750 bipolar I or II subjects. From these, we identified those who experienced a prospective depressive episode, followed by a remission (i.e., eight or more weeks of ÔrecoveredÕ status), followed by a second depressive episode. Where available, we then identified the next remission and third depressive episode.
Primary comparisons examined the first observed visit of the first and second depressive episodes. For comparability with previous reports, we calculated weighted kappa (for symptom measures) using quadratic weights, which is equivalent to intraclass correlation coefficient (18) . PearsonÕs correlation was used for continuous measures. To provide a more clinically interpretable measure of stability across episodes, we used logistic regression to examine association between presence or absence of each symptom at threshold levels at the first and second episode, adjusted for overall depressive severity in terms of CGI-S (or linear regression for continuous measures, such as percent of days anxious). To account for varying episode and recovery durations, a second logistic regression model was fit which included terms for interepisode interval and episode duration, as well as one limited to subjects with an interval of at least 365 days between the first and second analyzed visit. In a secondary analysis, we also examined agreement between first and third, and second and third, episode symptoms for the subset of patients (n = 149) with three prospectively observed episodes. Finally, to examine potential moderating effects of comorbidity, post-hoc analyses were run with inclusion of terms for current comorbid Axis I anxiety disorder or substance use disorder and for rapid cycling in the year prior to study entry.
We also conducted exploratory factor analysis of symptom items from the initial visit and examined the fit of a confirmatory factor model derived from the first-episode data to the second-episode data. We used methods appropriate for categorical variables with models fitted to a matrix of polychoric correlations using the robust weighted least square estimator, which has been shown to provide robust unbiased estimates for binary data (19) .
Analyses were conducted using Stata 10.0 (College Station, TX, USA); factor analyses were fitted in Mplus, v 5.1 (20) .
Results
Of the 4,107 subjects entering STEP-BD, 3,750 met criteria for bipolar I or II disorder. In this cohort, median follow-up duration was 383.5 days [interquartile range (IQR) 121-777]; median number of follow-up visits was 10 (IQR 4-19). Of the 3,750 subjects in this subset, 2,344 experienced a major depressive episode during prospective follow-up, 1,301 subsequently achieved recovery (median time to recovery 161 days; IQR 105-278), and 583 experienced a second depressive episode (median time to recurrence 153 days; IQR 70-296). For these 583 subjects (66.2% bipolar I), mean age was 40.6 (SD 12.1) years, and mean onset age was 16.6 (SD 8.2) years. A total of 62.6% were female and 92.8% were Caucasian; 35.9% had a history of psychotic symptoms, 73.4% had a lifetime history of rapid cycling, 41.2% had a history of suicide attempt, and 149 experienced a third depressive episode (median time to recurrence following recovery 168 days; IQR 69-309). Table 1 summarizes measures of agreement for individual mood symptoms between the first and second episode. Among depressive symptoms, the most prevalent in both episodes was loss of interest; the least prevalent was psychomotor agitation. Greatest stability was observed for neurovegetative symptoms, psychomotor symptoms, suicidal ideation, and depressed mood. Least stability was observed with loss of interest and fatigue. Percentage of days irritable and days anxious also demonstrated significant stability between episodes, as did overall severity in terms of CGI and count of DSM-IV mood symptoms. We also examined hypomanic ⁄ mixed symptoms present during major depressive episodes. Distractibility and flight of ideas were the most prevalent of such symptoms; the paucity of such symptoms limited precision of estimates of agreement. Finally, although observed in only 3% of episodes, psychosis was very stable between first and second episode.
To further clarify the role of recency effects (i.e., the stability of symptoms across episodes separated by another episode) for a subset of 149 subjects, we examined agreement between symptoms in episode 1 and 3, and episode 2 and 3 ( Table 2) . Results were generally consistent with those observed in the larger cohort. Incorporating current substance use disorders or Axis I anxiety disorders as covariates in the logistic regression models also did not meaningfully change results, nor did incorporating terms for number of intervening visits rather than intervening time between episodes (i.e., odds ratios for depressive symptoms changed by less than 10%) (Table 3) .
Finally, we conducted exploratory factor analysis of symptom item data. An exploratory threefactor model (interest-sleep-guilt) provided an excellent fit for the initial-visit data (root mean square error of approximation < 0.001). However, a confirmatory three-factor model derived from the )0.07-0.14 Columns 1 and 2 show the prevalence of each symptom in the first and second major depressive episode, respectively. Columns 3-7 show agreement between these two episodes, in terms of the kappa statistic. Remaining columns depict association between each symptom in the first and second episode, in terms of odds ratio (OR) and 95% confidence interval (CI). ÔAdjustedÕ OR refers to adjustment for overall depression severity in terms of symptom burden (i.e., number of syndromal symptoms). ÔOR > 365 daysÕ refers to analyses of the subset of patients for whom the two visits are separated by at least 365 days, in order to examine the impact of ÔrecencyÕ on symptom similarity. nc = not calculable (i.e., cells containing zero); CGI = Clinical Global Impression Scale. *Bonferonni-corrected p < 0.05 (i.e., p < 0.002).
**95% CI excludes 1 (i.e., p < 0.05). Shaded rows indicate symptoms with nominally significant (p < 0.05) association between first and third episodes and second and third episodes.
Stability of symptoms in major depressive episodes first-episode data did not fit the second-episode data. Likewise, constraining all factor loadings to be equal across the two episodes significantly deteriorated the fit of factor analytic models (whether these are derived from the first or from the second episode). This was due to substantial differences in symptom correlations in the first and second episodes. We concluded that symptom dimensions were not invariant, precluding a comparison of factor scores between episodes and mandating an analysis of one symptom at a time (as done above using kappas and logistic regression) to index stability and change between episodes.
Discussion
We identified evidence of consistency of many symptoms between two episodes but with wide variation in the extent of correlation, and substantially less correlation when the episodes are separated by another depressive episode. The most robust effects were observed for neurovegetative symptoms, psychomotor symptoms, thoughts of suicide, and depressed mood. While weighted kappa values indicated only modest agreement (0.15-0.28), odds ratios for these symptoms range from 1.5 to 3.7, indicating that the odds of a symptom being present in a subsequent depressive episode are up to 3.7-fold greater if a symptom is present in an initial episode. Conversely, fatigue and loss of interest in one episode showed little association with these symptoms in a subsequent episode. Our results are generally consistent with the previous work of Oquendo and colleagues (10), who examined 78 inpatients with MDD across two episodes in the only prior study to investigate individual symptoms. Anxiety, guilt, worthlessness, and poor concentration were quite stable across episodes, while fatigue clearly was not. However, we found no evidence that anhedonia was correlated, contrary to their report. This discordance may be a result of difference in diagnosis (MDD versus bipolar disorder) or treatment setting (inpatient versus outpatient). We also identified symptoms other than core DSM-IV depressive symptoms which may be stable across episodes. Anxiety and irritability are clearly correlated between episodes. Mixed ⁄ manic features, particularly distractibility, display some evidence of correlation between episodes, though considerably less than a previous small study of bipolar inpatients suggests (13) ; such estimates should be considered preliminary given the relative paucity of such symptoms overall. Notably, total depression severity (in terms of CGI) displays modest, but significant, stability across episodes.
One clinically important finding from this analysis is the significant stability of suicidal ideation across adjacent depressive episodes. While prediction of suicide attempts is difficult (21) , the substantial mortality associated with suicide in bipolar disorder (22) mandates a continued search for clinical predictors. Consistent with prior studies among inpatients (10) and recovered outpatients with MDD (23), our results suggest that the presence of suicidal ideation in one depressive episode should raise the clinicianÕs concern for suicidal ideation in the subsequent episode.
We attempted to determine whether dimensions or groups of symptoms are correlated across the two episodes using exploratory and confirmatory factor analyses. As the relationships (correlations) between individual symptoms were not stable between episodes, however, it was not possible to examine the consistency of symptom dimensions. This inconsistency across episodes implies that using groups of symptoms to distinguish bipolar depression, or to parse it into subtypes, may be problematic because the relationships between symptoms change over time.
Taken together, this analysis does support the stability of many but not all depressive symptoms, as well as some symptoms, such as irritability and anxiety, not previously investigated for consistency in depressive episodes. Our findings are generally consistent with previous investigations (7, 8, 10) , although we are unable to investigate the precise subtypes (e.g., endogenous and atypical depression) studied by Coryell and colleagues (7) because not all of these features were collected in STEP-BD. As a predominantly outpatient study, the prevalence of psychosis is low, though nonetheless it identifies stability across two (although not three) episodes, as others have reported in MDD (24) and bipolar disorder (25) . We also find support for the concept of ÔrecencyÕ proposed by Coryell and colleagues (7) , which posits that symptom similarity diminishes with greater separation between episodes. Limiting our analysis to episodes separated by a year or more yielded less symptom stability, as did examining a third prospective episode.
Several caveats bear consideration in interpreting our results. First, as we elected to limit the analysis to syndromal (threshold) or subthreshold symptoms, we may underestimate the degree of correlation between episodes which would be detected using a broader ordinal scale. While STEP-BD did include the Montgomery-Å sberg Depression Rating Scale (26) , these assessments were performed on a quarterly basis and so would not be able to capture recurrent episodes in most cases. We elected to focus on individual symptoms, rather than subtypes per se, because of abundant evidence of overlap even among recognized descriptors such as atypical and melancholic (27) , a strategy further supported by the results of our SEM analysis. Second, the use of a single (crosssectional) assessment in each episode fails to capture the fluctuation in symptoms which may be observed within a single episode. For example, some patients could initially experience hypersomnia, followed by insomnia, within a single episode. On the other hand, the approach employed here is more readily interpretable than one looking across all episodes [for example, using a time-series approach (28) ]. Finally, we cannot entirely exclude medication effects, which are likely to be correlated across episodes-i.e., stability in patient treatment could account for some of these effects if symptoms are actually related to side effects. However, incorporating individual pharmacotherapies as covariates in regression models did not meaningfully change measures of association (results not shown).
In spite of these limitations, these results suggest the phenotypic complexity of bipolar depression. As Coryell and colleagues pointed out (7), they illustrate another means by which psychiatric nosology may be validated even in the absence of biological gold standards. Moreover, further investigation of the neurobiology of the more stable symptoms, or groups of symptoms, may be particularly useful in elucidating the pathophysiology of bipolar disorder.
